Here again, CFM-4.16 caused a generally higher increase in CARP-1 levels, activation of SAPKs, PARP-1 cleavage in parental or Everolimus-resistant RCC cells when compared with the cells that were treated with CFM-4. The gene discussed is PARP1; the disease is renal cell adenocarcinoma.